ATS View
한국어

Daewoong Pharma KRX:069620KOSPI

대웅제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h23
Articles, 7 days24
DART filings, 7 days2
Articles tracked24since Sep 11

In Q2 2026, Daewoong Pharma reported revenue of ₩448bn, up 10.6% year on year, and operating profit of ₩68.1bn. Daewoong Pharma (대웅제약) appeared in 24 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Sep 15 with 23 articles. It was most often mentioned alongside Medy-Tox.

Daewoong Pharma quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩448bn+10.6%₩68.1bn₩19.9bn
Q1 2026₩378bn+6.0%₩22.2bn₩25.5bn
Q4 2025 derived₩397bn+7.9%₩43.3bn₩85.7bn
Q3 2025₩412bn+14.9%₩56.9bn₩47.3bn
Q2 2025₩405bn+12.5%₩57.9bn₩40.1bn
Q1 2025₩356bn+6.2%₩38.7bn₩19.8bn
Q4 2024 derived₩368bn+1.7%₩38.7bn−₩11.5bn
Q3 2024₩358bn+5.2%₩37.3bn₩28.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Daewoong Pharma top stories 2 weeks, by number of outlets

  1. 1
    대웅제약, 한·일 당뇨병 전문가와 CGM 최신 지견 공유
    7 outlets · 7 articlesFirst report Sep 15 08:58 핀포인트뉴스
  2. 2
    대웅제약, 한·일 석학과 '혈당 관리 패러다임 전환' 조명
    6 outlets · 6 articlesFirst report Sep 15 09:05 뉴스1
  3. 3
    대웅제약, 한·일 당뇨병 전문가 초청 CGM 웹 심포지엄 개최
    3 outlets · 3 articlesFirst report Sep 15 09:07 아시아타임즈
  4. 4
    대웅제약, 한·일 당뇨병 석학과 CGM 기반 혈당관리 새 흐름 조명
    1 outlets · 1 articlesFirst report Sep 15 09:42 바이오타임즈
  5. 5
    대웅제약, 한·일 전문가와 CGM 최신 진료 흐름 논의
    1 outlets · 1 articlesFirst report Sep 15 09:48 메디코파마
  6. 6
    대웅제약, 韓日 최신 당뇨 치료 흐름 제시
    1 outlets · 1 articlesFirst report Sep 15 10:49 메디칼업저버

Latest Daewoong Pharma news Korean headlines